CHEK2 and complete blood cell count: In addition, studies focusing on, for example, the molecular copy number aberration profile of CHEK2‐related tumors should further shed light on potential biological mechanisms underlying the observed increased CBC risk and possible worse survival in CHEK2 c.1100delC carriers.